Mission Therapeutics has divested MTX652, a Phase 2-ready selective USP30 inhibitor for Acute Kidney Injury (AKI), to ASX-listed renal specialist...
New collaboration embeds Canary Speech's vocal biomarker technology into NeuroLexIQ's Concussion Probability Report, flagging potential brain injuries at a client's...
7C11 antibody builds on APOE Christchurch variant biology associated with resilience to Alzheimer’s disease, including effects on tau, amyloid and...
Brainify.AI's new longevity platform brings measurable cognitive wellness to The Longevity Suite's Riyadh clinic, marking its debut in the luxury...
This appointment reflects the company's continued growth through investment in leadership that pairs deep scientific credibility with real-world R&D experience...
LOS ANGELES, July 13, 2026 /PRNewswire/ -- Nervonik, Inc., a medical technology company developing a next-generation peripheral nerve stimulation platform...
LOS ANGELES, July 13, 2026 /PRNewswire/ -- Nervonik, Inc., a medical technology company developing a next-generation peripheral nerve stimulation platform...
SHELTON, CT / ACCESS Newswire / July 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
Fully non-hallucinogenic, oral, non-scheduled 5-HT2A neuroplastogen differentiates BETR-001 from every other 5-HT2A agonist program; depression and other psychiatric disorders retained...
Pharmacodynamic effects in the human brain and energy metabolism biomarker data presented at AAIC support further clinical development of VNA-318...
Founded by two former enterprise executives, SoliVana combines 16 evidence-aligned therapies across 9 private rooms to address the stress and...
A first-of-its-kind cross-sector initiative — convened by the nation's leading women's health information source — to drive systemic change in...
New awards program honors the clinicians, executives, and operators redefining how patients access care, launched on the heels of Assort's...
Optimized Oral Formulation Demonstrates Favorable Oral Bioavailability Together with Robust Brain and Liver Distribution Following Oral Administration MIAMI, FL /...
COPENHAGEN, Denmark, July 10, 2026 (GLOBE NEWSWIRE) -- Nine new Challenge Programme grants from the Novo Nordisk Foundation will support...
TORONTO, July 9, 2026 /CNW/ - The Centre for Aging + Brain Health Innovation (CABHI), powered by Baycrest, is awarding...
Statewide "Bring It Home for Kids" campaign expands access to early language, learning and family support programs during the years...
Dysport® achieved statistically significant topline Phase III results, meeting primary endpoints in both episodic (E-BEOND) and chronic (C-BEOND) migraineDysport is...
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming...
Grounded in evidence and guided by leading tinnitus experts, the online education platform will train current and future providers starting...